Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

Islet, Brighthaven Ventures ink license deal for Phase II SGLT2 inhibitor remogliflozin By PBR Staff Writer
Islet Sciences has entered into a license agreement with Brighthaven Ventures (BHV) for exclusive rights to develop and commercialize SGLT2 inhibitor remogliflozin, which is currently Phase IIb development for patients with type 2 diabetes and non-alcoholic steatohepatitis (NASH).
Contract Research & Services > Contract Services > News
Ipsen secures option to buy Canbex Therapeutics By PBR Staff Writer
French pharmaceutical firm Ipsen has entered into option agreement to acquire 100% shares of UK's Canbex Therapeutics following completion of the Phase IIa trial of its orally active small molecule compound VSN16R, which is designed to treat spasticity in people with multiple sclerosis (MS).
Contract Research & Services > Contract Services > News Merck, MPP to expand access to pediatric formulations of HIV drug raltegravir By PBR Staff Writer
Merck has signed an agreement with the Medicines Patent Pool (MPP) to allow the use of its HIV drug, Isentress (raltegravir), to treat children aged four weeks to 12 years in developing countries.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Ipsen secures option to buy Canbex Therapeutics
By PBR Staff Writer
French pharmaceutical firm Ipsen has entered into option agreement to acquire 100% shares of UK's Canbex Therapeutics following completion of the Phase IIa trial of its orally active small molecule compound VSN16R, which is designed to treat spasticity in people with multiple sclerosis (MS).
Contract Research & Services > Contract Services > News
Merck, MPP to expand access to pediatric formulations of HIV drug raltegravir
By PBR Staff Writer
Merck has signed an agreement with the Medicines Patent Pool (MPP) to allow the use of its HIV drug, Isentress (raltegravir), to treat children aged four weeks to 12 years in developing countries.
Contract Research & Services > Contract Services > News
Atlant Clinical Services
We provide a comprehensive range of services in clinical trials:
Contract Research & Services > Contract Services > Products
Ferring buys two Phase III ready orthobiologic products from BioSET
By PBR Staff Writer
Ferring Pharmaceuticals has acquired the assets of BioSurface Engineering Technologies (BioSET) including two Phase III ready orthobiologic product candidates designed to improve bone repair.
Contract Research & Services > Contract Services > News
Teva to commercialize Eagle’s bendamustine rapid infusion product to treat CLL and NHL
By PBR Staff Writer
Teva Pharmaceutical Industries has entered into an exclusive license agreement for Eagle Pharmaceuticals' EP-3102, a bendamustine hydrochloride (HCl) rapid infusion product, designed to treat chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL).
Contract Research & Services > Contract Services > News
Sanofi, Lead Pharma to develop new autoimmune treatments
By PBR Staff Writer
French healthcare firm Sanofi has entered into an agreement with Dutch biotech firm Lead Pharma to discover, develop and commercialize treatments for a range of autoimmune diseases including rheumatoid arthritis, psoriasis and inflammatory bowel disease.
Contract Research & Services > Contract Services > News
Lupin, Celon to jointly develop generic asthma drug
By PBR Staff Writer
India-based drugmaker Lupin has entered into an agreement with Polish biopharmaceutical firm Celon Pharma to jointly develop and market fluticasone/salmeterol dry powder inhaler (DPI) product, a generic version of GlaxoSmithKline's (GSK) asthma drug Advair Diskus.
Contract Research & Services > Contract Services > News
Merck gets full promotional responsibility for Erbitux in Japan
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and Merck have agreed to end co-promotion of Erbitux (cetuximab) in Japan, as well as transfer full promotional responsibilities of the product to Merck as of 01 May 2015.
Contract Research & Services > Contract Services > News
Voyager, Genzyme to develop new AAV gene therapies for patients with CNS disorders
By PBR Staff Writer
Voyager Therapeutics and Genzyme have entered into $845m collaboration to develop and commercialize new adeno-associated virus (AAV) gene therapies for patients suffering from severe central nervous system (CNS) disorders.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250